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Abstract
Type 2 diabetes is a growing public health concern and accounts for approximately 90% of
all the cases of diabetes. Besides insulin resistance, type 2 diabetes is characterized by a
deficit in β-cell mass as a result of misfolded human islet amyloid polypeptide (h-IAPP)
which forms toxic aggregates that destroy pancreatic β-cells. Heat shock proteins (HSP)
play an important role in combating the unwanted self-association of unfolded proteins. We
hypothesized that Hsp72 (HSPA1A) prevents h-IAPP aggregation and toxicity. In this
study, we demonstrated that thermal stress significantly up-regulates the intracellular
expression of Hsp72, and prevents h-IAPP toxicity against pancreatic β-cells. Moreover,
Hsp72 (HSPA1A) overexpression in pancreatic β-cells ameliorates h-IAPP toxicity. To test
the hypothesis that Hsp72 (HSPA1A) prevents aggregation and fibril formation, we estab-
lished a novel C. elegansmodel that expresses the highly amyloidogenic human pro-IAPP
(h-proIAPP) that is implicated in amyloid formation and β-cell toxicity. We demonstrated that
h-proIAPP expression in body-wall muscles, pharynx and neurons adversely affects C. ele-
gans development. In addition, we demonstrated that h-proIAPP forms insoluble aggre-
gates and that the co-expression of h-Hsp72 in our h-proIAPP C. elegansmodel, increases
h-proIAPP solubility. Furthermore, treatment of transgenic h-proIAPP C. elegans with
ADAPT-232, known to induce the expression and release of Hsp72 (HSPA1A), significantly
improved the growth retardation phenotype of transgenic worms. Taken together, this study
identifies Hsp72 (HSPA1A) as a potential treatment to prevent β-cell mass decline in type 2
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select compounds that attenuate h-proIAPP aggregation and toxicity.
Introduction
Recently, the number of people with diabetes worldwide reached 382 million and by 2035 this
number will increase to 592 million (International Diabetes Federation); 90% of whom have
type 2 diabetes. An important characteristic of type 2 diabetes is a deficit in β-cell mass as a
result of misfolded human islet amyloid polypeptide hormone (h-IAPP, also called amylin),
which forms toxic aggregates that destroy pancreatic β-cells [1]. β-cell apoptosis begins early in
the disease process and at diagnosis 40–60% of β-cell volume may already have been lost [2]. h-
IAPP is a 37-amino acid hormone co-secreted with insulin by pancreatic β-cells, and is initially
synthesized as a 89-amino acid pre-prohormone containing a 22 amino-acid signal peptide
and two short flanking peptides that are later cleaved [3]. The signal peptide is cleaved in the
endoplasmic reticulum (ER), where pre-proIAPP is converted into proIAPP and then con-
verted into IAPP in secretory granules [3]. ProIAPP by itself is highly amyloidogenic and its
aggregation could be the starter event of amyloid formation [4, 5]. In vitro studies demon-
strated that proIAPP aggregates are toxic to pancreatic beta cells [6]. Immune electron micro-
scopic studies with antibodies specific to proIAPP, evidenced the presence of proIAPP together
with IAPP in intracellular amyloid [4]. Human, feline and non-human primate forms of IAPP
are the only forms with the capacity to oligomerize and form aggregates.
Insulin resistance and hyperglycemia characteristics of type 2 diabetes not only induce insu-
lin production but also increase IAPP production, which demands higher concentrations of
molecular chaperones to help with folding activities. This higher demand for chaperones,
within β-cells already exhausted due to hyperglycemic stress, may result in β-cell overload ulti-
mately leading to the accumulation of misfolded IAPP aggregates and toxicity. Moreover, avail-
ability of chaperones are decreased in states such as cell stress and aging [7]. Therefore,
increasing the levels of chaperones in order to protect pancreatic β-cells against cell damage
provides an attractive therapeutic target for the treatment of type 2 diabetes. Especially impor-
tant is Hsp72 (HSPA1A), the stress-inducible form of the HSP70 super-family, that acts early
in the life of proteins binding to short hydrophobic segments preventing misfolding and aggre-
gation. Hsp72 (HSPA1A) also has refolding activities and promotes the degradation of mis-
folded proteins and aggregates [8]. Among the substances that induce the expression of Hsp72
(HSPA1A), is a group of plant extracts called adaptogens characterized by their property to
promote a non-specific adaptive response to resist stressful conditions [9]. The most exten-
sively studied adaptogens are: Eleutherococcus senticocus, Schisandra chinensis and Rhodiola
rosea, which are the active ingredients of ADAPT-232 [10]. Here we present evidence that
ADAPT-232 has the potential for translation to a novel therapy to prevent IAPP toxic
aggregation.
In this study, Caenorhabditis elegans (C. elegans) was chosen as a model system to charac-
terize the aggregation of h-proIAPP and to establish the role of molecular chaperones in pre-
venting or ameliorating h-proIAPP aggregation over the traditional rat models for diabetes for
several reasons: Onset of diabetes in the traditional rat model takes weeks as compared to days
in C. elegans. The C. elegansmodel system allows researchers to more easily study the effect of
diabetes over the entire life span of the animal, since it has a relatively short life cycle of approx-
imately 3 days. The size of C. elegans (1 mm long) and transparency allows the expression and
easy visualization of fluorescently tagged proteins. C. elegans has also previously been used as
an in vivomodel system to study diseases related with protein aggregation such as
Hsp72 Prevents IAPP Aggregation and Toxicity
PLOS ONE | DOI:10.1371/journal.pone.0149409 March 9, 2016 2 / 21
study design, data collection and analysis, decision to
publish or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
neurodegenerative diseases [11]. Finally, the C. elegansmodel system is less expensive to pur-
chase and maintain than the traditional rat model and the large number of eggs laid by C. ele-
gans hermaphrodites allows cultivation of a large number of animals in a short period of time.
Also, the worms are easy to maintain in the laboratory using agar plates with E. coli as a food
source. Here, we demonstrated that h-proIAPP expression in body-wall muscles, pharynx and
neurons results in a growth retardation phenotype that was significantly improved by treat-
ment with ADAPT-232. Moreover, h-proIAPP forms insoluble aggregates inside the worm
and the co-expression of human Hsp72 (h-Hsp72) increases proIAPP solubility.
Materials and Methods
Institutional animal care & use committee (IACUC) and animal research
ethics statement
Work with the invertebrate nematode model organism, C. elegans, does not require Institu-
tional Animal Care and Use Committee (IACUC) approval, as stated by the Public Health Ser-
vice Policy on Humane Care and Use of Laboratory Animals (PHS).
Cells and culture conditions
Beta-TC-6 cells (ATCC, Manassas, VA) were maintained in monolayer cultures in HEPES-
buffered Dulbecco’s modified Eagle’s medium (Life Technologies, Grand Island, NY) supple-
mented with 15% heat-inactivated fetal bovine serum (Life Technologies), 100 IU/ml penicillin
and 100 μg/ml streptomycin (Life Technologies). Cells were maintained at 37°C humidified
atmosphere with 5% CO2. h-IAPP (Bachem, King of Prussia, PA) was dissolved in water and
immediately added it to the culture medium of β-cells at various concentrations.
Cell viability assays
Cell viability was measured in cells plated on 96-well tissue culture plates by MTS assay (Pro-
mega Corp., Madison, WI). MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt] was utilized according to the manufacturer’s
instructions.
Western blot analysis
Total cell extracts (50μg) from Beta-TC-6 cells were isolated according to standard protocol
(Cell Signaling Technology, Danvers, MA); fractionated by electrophoresis on 12% SDS poly-
acrylamide gels; electroblotted to PVDF membrane (GE healthcare, Piscataway, NJ) and
probed with anti-Hsp72 (Enzo Life Sciences, Farmingdale, NY), and anti-Hsp25 (Enzo Life Sci-
ences) antibodies. To detect IAPP expression, membranes were probed with a polyclonal anti-
body raised against amino acids 40–89 of IAPP precursor of human origin (Santa Cruz
Biotechnology, Dallas, TX) that cross reacts to a lesser extent with mouse IAPP. Protein load-
ing control used was β-actin (Abcam, Cambridge, MA). Appropriate horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used in
the study. Protein bands were visualized by chemiluminescence (Thermo Scientific, Rockford,
IL), films were developed and image processor Quantity One (Version 4.6) was used to scan
and to compare expression levels.
Transfection procedures
Beta-TC-6 cells were plated on 96-well tissue culture plates and allowed to attach overnight.
When 70–80% confluency was reached, cells were transfected with h-proIAPP cDNA clone
Hsp72 Prevents IAPP Aggregation and Toxicity
PLOS ONE | DOI:10.1371/journal.pone.0149409 March 9, 2016 3 / 21
(vector pCMV6-XL5, Origene, Rockville, MD) or m-proIAPP cDNA clone (vector pCMV6-
Kan/NEO, Origene) or h-Hsp72 cDNA clone (vector pEGFP, Addgene, Cambridge, MA) or
both h-proIAPP and h-Hsp72 vectors. Transfection complexes were prepared with Opti-MEM
(Life Technologies), and Lipofectamine LTX and PLUS reagent (Life Technologies), according
to the manufacturer’s instructions. Medium was changed after 4–6 hours. After 48 hours of
incubation we used MTS assay to evaluate cell viability.
C. elegans strains and culture techniques
The following strains of C. elegans used in this study including, pha-1(e2123) [12]; him-5
(e1490) [13]; and lite-1(ce314) [14] were obtained from Prof. Renee Garcia (Texas A&M Uni-
versity). Animals were maintained on NGM plates seeded with Escherichia coli strain OP50 at
20°C [15]. Further details on maintenance and culture techniques can be found in the Support-
ing Information section.
Constructs
Human and mouse preproIAPP cDNA clones (Origene, Rockville, MD) were subcloned
into BamH1 sites of expression vector pSX95.77YFP using the In-FusionTM PCR cloning
system (Clontech, Mountain View, Ca). For h-proIAPP cloning we use h-proIAPP forward
(50-CGACTCTAGAGGATCCATGGGCATCCTGAAGCTGCAAG-30) and reverse (50-
CCAATCCCGGGGATCCAAGGGGCAAGTAATTCAGTGG-30) primers. For mouse-
proIAPP (m-proIAPP) cloning we use m-proIAPP forward (50-CGACTCTAGAGGATCC
ATGATGTGCATCTCCAAACTGCCAGC-30) and reverse (50-CCAATCCCGGGGATCC
AACGAGTAAGAAATCCAAGG-30) primers. The resulting constructs were digested with
Sal I, blunt-ended and then ligated with the Gateway Vector Conversion Reading Frame
Cassette C.1 (Life Technologies, Grand Island, NY) to generate Gateway destination vectors
pNG1 and pNG2 that contained the human and mouse preproIAPP clones, respectively.
Entry clones pLR22, pLR25 and pLR35 contained the C. elegans promoter regions of lev-11
(body-wall muscles), tnt-4 (pharynx) and aex-3 (pan-neuronal), respectively. Promoter
sequences in pLR22, pLR25 and pLR35 were recombined into pNG1and pNG2 using LR
recombination reaction, to generate C. elegans transgenic tissue-specific plasmids. Three
human IAPP plasmids: pPR3 (lev-11 promoter), pPR4 (tnt-4 promoter) and pPR5 (aex-3
promoter); and three mouse IAPP plasmids: pPR8 (lev-11 promoter), pPR9 (tnt-4 promoter)
and pPR10 (aex-3 promoter) were generated. To generate a tissue-specific expression of
YFP, construct pSX95.77YFP was digested with Sal I, blunt-ended and ligated with Gateway
C.1 cassette to generate pNG3. The promoter sequence in pLR22 (lev-11 promoter, body-all
muscles) was recombined into pNG3, using LR recombination reaction to generate plasmid
pPR18. To generate tissue-specific expression of the h-Hsp72 plasmid; the h-Hsp72 insert
was amplified using the pOTB7 vector (Life Technologies) that contained the Hsp72 clone.
The cDNA fragments were subcloned into BamH1 sites of expression vector pTG24 by In-Fu-
sionTM PCR cloning using h-Hsp72 forward (50-CGACTCTAGAGGATCCATGGCCAAA
GCCGCGGCGATCGG-30) and reverse (50-CCAATCCCGGGGATCCATCCACCTCCTCAA
TGGTGGG-30) primers. The resulting constructs were digested with Xbal, blunt-ended and
ligated with Gateway C.1 cassette to generate pNG4 that contained the h-Hsp72 sequence.
Entry clone pLR22 was recombined using LR recombination reaction into pNG4 to generate
tissue specific plasmid pPR21 (lev-11 promoter). For a complete list of primers used in this
study see S1 Table.
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Transgenics
Plasmids containing the construct of interest were injected into 1-day-old adult pha-1(e2123);
him-5(e1490); lite-1(ce314) hermaphrodites following standard procedures [16]. 50 ng/μl of the
pha-1 rescuing plasmid, pBX1, was used as a transgenic marker, as previously described [17].
pUC18 was used as carrier DNA to bring each injection mixture to a final concentration of 200
ng/μl.
Growth retardation phenotype
Ten to fifteen gravid 1- to 3-day-old adult hermaphrodites were placed on NGM agar plates or
NGM ADAPT-supplemented plates with OP50 as a food source and treated with one drop of
bleaching solution in order to induce the release of the eggs. Larvae were synchronized and sev-
enty-two hours after treatment, larvae stage or adult stage was determined.
Image acquisition
One-day-old adult animals were paralyzed using sodium azide, mounted on 2% agarose pads
and covered with a cover slip. Images of fluorescent animals were taken using an Olympus
Fluoview 300 confocal microscope with a 60X apochromat water immersion objective. The
YFP-labeled structures were excited at 488 nm and the fluorescence was collected through a
560–600 nm band-pass filter. All images were taken at 10% power intensity; PMT, gain and off-
set adjusting were held constant. Each confocal slice consisted of 512 (X) x 512 (Y) pixels. We
scanned completely through the animals at 0.5μm Z-axis increments. Mean fluorescence inten-
sity was measured using a sum intensity projection in ImageJ on all the planes of the acquired
stacks of the different structures. Maximum intensity projections were created using ImageJ on
all the planes of the acquired stacks to output images for visualization. Differential interference
contrast (DIC) images using 60X magnification were taken to visualize structures.
Fluorescence recovery after photobleaching (FRAP) analysis
FRAP analysis was performed as previously described [18, 19] and described in detail in the
Supporting Information section. Images were obtained using the Olympus Fluoview 300 confo-
cal microscope and analyzed using ImageJ.
Statistical analysis
Data were evaluated for statistical significance using Student t-test for pair wise comparison of
two groups and ANOVA post-hoc Tukey test for comparison of 3 groups. Data are expressed
as the mean ± SD, unless otherwise specified.
Results
Heat shock treatment reduces exogenous h-IAPP toxicity against
pancreatic β-cells
Mouse insulinoma Beta-TC-6 cells (ATCC) were exposed to various concentrations of exoge-
nous h-IAPP. Similar to the report by Lorenzo et al. [20], toxicity was initially detected at a
concentration of 5 μM h-IAPP (determined by trypan blue exclusion assay) and complete cell
death occurred at 40 μM (Fig 1A). In order to quantitatively measure h-IAPP toxicity against
Beta-TC-6 cells, we calculated h-IAPP IC50 using MTS cell proliferation assay (Promega). The
IC50 for h-IAPP was calculated at 7.68 ± 4.54 μM (Fig 1B). To select the optimum heat shock
treatment to be used in the prevention of h-IAPP toxicity, we evaluated the expression levels of
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inducible chaperones due to thermal stress on Beta-TC-6 cells. We found that the levels of
Hsp72 (HspA1A) and Hsp25 (HspB1) are absent under basal conditions and their expression
was up-regulated after thermal stress, with the highest levels found after 45 min of heat shock
at 43°C (Fig 1C; top panel). We also found that heat shock at 43°C affects Beta-TC-6 cells via-
bility, as determined by MTS assay 24 hours post heat shock treatment (Fig 1C; middle and
bottom panels). Cell viability was not affected after 30 min of heat shock; thus, this treatment
was selected to evaluate the role of Hsp72 (HSPA1A) in preventing h-IAPP toxicity. Having
demonstrated that heat stress increased the levels of Hsp72 (HSPA1A), we then established
whether this induction protects β-cells against exogenously added h-IAPP. For this purpose,
Beta-TC-6 cells were plated and 24 hours later were heat shocked at 43°C for 30 min and then
returned to the incubator for an additional 24 hours to allow for Hsp72 expression. Another
Fig 1. Heat shock treatment protects pancreatic β-cells against h-IAPP toxicity. A. Beta-TC-6 cells were exposed to various concentrations of
exogenously added h-IAPP for a 24 hours period. Cell viability was determined by trypan blue exclusion assay. Live cells exclude trypan blue, while dead
cells take up trypan blue and appear blue when observed under a white light microscope. Data is a representative experiment from at least three
independently performed experiments with similar results. Scale bars represent 100 μm. B. Beta-TC-6 cells were exposed to various concentrations of h-
IAPP. Twenty-four hours later, cell viability was measured using MTS cell proliferation assay. IC50 was calculated as the concentration of h-IAPP required to
obtain 50% of its maximum toxic effect (± SD). C. Beta-TC-6 cells were exposed at 43°C for 30, 45 and 60 minutes and the expression of Hsp72 and Hsp25
were measured byWestern blot 24 hours after heat exposure (top panel). Beta-TC-6 cells were exposed to heat shock at 43°C for 30, 45 and 60 minutes and
cell viability was determined by MTS assay 24 h after heat exposure (middle panel; filled bars). Phase contrast microscopy of Beta-TC-6 cells exposed to
heat shock at 43°C for 30, 45 and 60 minutes 24 h after heat exposure (bottom panel). Data is a representative experiment from at least three independently
performed experiments with similar results. Scale bars represent 50μm.D. Heat treatment at 43°C for 30 minutes protects Beta-TC-6 cells against
exogenous h-IAPP toxicity. Beta-TC-6 cells were heat shocked at 43°C for 30 min (filled bars) or maintained at normal temperature 37°C for 30 min (open
bars). On day 2, cells were treated with various concentrations of h-IAPP. After 24 h of incubation, cell viability was assessed by MTS assay. Data represents
the sum of three of three independently performed experiments. *p<0.05; **p<0.01 versus respective controls, n = 3.
doi:10.1371/journal.pone.0149409.g001
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set of cells were kept at 37°C for 30 min to serve as a control. On day 3, various concentrations
of h-IAPP solution were applied to the cell culture medium. After 24 h of incubation, cell via-
bility was assessed by MTS assay. We demonstrated that heat shock significantly reduced the
toxic effect of h-IAPP (Fig 1D). In a separate experiment, we demonstrated that there is a sig-
nificant variation in fluorescence intensity of cells expressing DsRed-h-IAPP (S1 Fig). We fur-
ther demonstrated that cells that expressing the highest red fluorescence intensity were round
and detached suggesting that they were dead due to h-IAPP toxicity (S1 Fig).
Hsp72 ameliorates toxicity induced by endogenous expression of h-
IAPP in pancreatic β-cells
To establish the effect of endogenously expressed h-IAPP in Beta-TC-6 cells, we transiently
transfected these cells with plasmids expressing human proIAPP (vector pCMV6-XL5; Ori-
gene) and mouse proIAPP (vector pCMV6-Kan/NEO, Origene), empty vector (pCMV6-XL5;
Origene) served as a transfection control. Transfection complexes were prepared with Opti-
MEM (Gibco), and Lipofectamine LTX with Plus reagent (Life Technologies), according to the
manufacturer’s instructions. Medium was changed after 4–6 hours and cells were incubated for
48 hours. At the end of the transfection period, cell viability was assessed by MTS assay. We
demonstrated that h-IAPP over-expression significantly induced Beta-TC-6 cell death as com-
pared to controls, p<0.01 (Fig 2A and 2B); while over–expression of m-IAPP was less toxic
(Fig 2A). To evaluate the role of Hsp72 in h-IAPP toxicity, we co-transfected Beta-TC-6 cells
Fig 2. Hsp72 reduces endogenous h-IAPP toxicity in pancreatic β-cells. A. Beta-TC-6 cells were transfected and cell viability was assessed by MTS
assay. Data represent percentage of live cells ± SD (filled bars) when transfected with vector pCMV6-XL5 (control) or human Hsp72::EGFP cDNA clone or
m-proIAPP cDNA clone or h-proIAPP cDNA clone or both h-proIAPP and human Hsp72::EGFP vectors. Data represents the sum of three independently
performed experiments. **p<0.01 versus respective controls, n = 3. B. At the end of the transfection period, phase contrast and fluorescence images were
obtained. Data is a representative experiment from at least three independently performed experiments with similar results. Scale bars represent 50 μm. C.
Beta-TC-6 cells were transfected with empty vector pCMV6-XL5 (control), or m-proIAPP cDNA clone or h-proIAPP cDNA clone or with both h-proIAPP and
human Hsp72::EGFP vectors. After transfection, samples were collected and examined for the expression of h-IAPP byWestern blot analysis. Data is a
representative experiment from at least three independently performed experiments with similar results.D. Beta-TC-6 cells were transfected with empty
vector pCMV6-XL5 (control), or human Hsp72::EGFP cDNA clone, or with both h-proIAPP and human Hsp72::EGFP vectors. After transfection, samples
were collected and examined for the expression of Hsp72 byWestern blot analysis. Data is a representative experiment from at least three independently
performed experiments with similar results.
doi:10.1371/journal.pone.0149409.g002
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with h-proIAPP and Hsp72::EGFP plasmids; medium was changed after 4–6 hours and cells
were incubated for 48 hours. At the end of the transfection period, cell viability was assessed by
the MTS assay. This experiment revealed that h-Hsp72 over-expression significantly prevented
h-IAPP-induced toxicity, as compared to cells transfected with h-IAPP alone, p<0.01 (Fig 2A
and 2B). Western blot analysis did not detect any significant differences in the expression levels
of h-IAPP or Hsp72 when transfected alone or in combination (Fig 2C and 2D). Meanwhile,
the antibody used to detect IAPP was effective at detecting h-IAPP, but did not detect m-IAPP
(Fig 2C).
Constitutive expression of human but not mouse-proIAPP in C. elegans
induces insoluble aggregates
To generate a proIAPP C. elegansmodel system, cDNA encoding h-proIAPP and m-proIAPP,
containing the human and mouse signal peptide, respectively, were inserted in vector
pSX95.77YFP, which contains yellow fluorescence protein gene positioned in front of the C.
elegans unc-54 3’UTR (Fig 3A). The proIAPP genes were translationally fused to the 5’-end of
the YFP coding sequence (Fig 3A). Positive clones were identified by colony PCR (S2 Fig) and
sequenced (Fig 3B and 3C). Human and mouse pSX95.77YFP-proIAPP constructs were ligated
into Gateway Cassette C.1 upstream of h-proIAPP and m-proIAPP coding sequences, to create
vectors pNG1 and pNG2, respectively (Fig 3A). pNG1 and pNG2 were recombined with
pLR22, pLR25 and pLR35 to create h-proIAPP plasmids: pPR3, pPR4 and pPR5 and m-
proIAPP plasmids: pPR8, pPR9 and pPR10 (Fig 3A). Transgenic h-proIAPP C. elegans animals
were generated by gonad microinjection of 20ng/μl of plasmids pPR3, pPR4 and pPR5. Trans-
genic m-proIAPP C. elegans animals were generated by gonad microinjection of 20ng/μl of
plasmids pPR8, pPR9 and pPR10. C. elegans injected only with 50ng/μl of plasmid pBX1 was
used as a negative control (pBX1 control).
We observed significantly higher fluorescence intensity in the animal body-wall muscles,
vulva muscles and anal depressor muscles when h-proIAPP was expressed under the muscle-
specific lev-11 promoter (Fig 4A; right panels and Fig 4B), as compared to animals in which
m-proIAPP was expressed under the same promoter (Fig 4A; left panels and Fig 4B). Similarly,
h-proIAPP expression in pharynx muscles under the pharyngeal-specific tnt-4 promoter,
exhibited significantly higher fluorescence intensity (Fig 4A; right panels and Fig 4B) as com-
pared to the m-proIAPP expression under the same promoter (Fig 4A; left panels and Fig 4B).
Expression of proIAPP driven by the aex-3 pan-neuronal promoter was secreted from neurons
into the body cavity where it was taken up by coelomocytes, known to have a phagocytic func-
tion similar to macrophages of vertebrates. Coelomocytes found in the transgenic h-proIAPP
C. elegansmodel were more intensely fluorescent (Fig 4A; right panels and S3 Fig) than coelo-
mocytes in the m-proIAPP C. elegansmodel (Fig 4A; left panels). Differences in fluorescence
intensity cannot be explained by differences in expression levels, since both h-proIAPP and m-
proIAPP C. elegansmodels showed similar proIAPP mRNA levels determined by RT-PCR (S4
Fig). Expression of plasmids under the inducible hsp-16-2 promoter resulted in high expres-
sion of pro-IAPP in the pharynx, body wall muscles and intestinal walls after animals were
exposed to heat stress at 33°C for 90 minutes (S5 Fig). Transgenic h-proIAPP C. elegans ani-
mals exhibited significantly more aggregates than transgenic m-proIAPP C. elegans animals,
particularly in the pharynx (S5 Fig; right panels). To determine if the higher fluorescence inten-
sity found in the transgenic h-proIAPP C. elegansmodel correspond to the formation of insol-
uble h-proIAPP aggregates, we used FRAP analysis. Fluorescent regions that do not recover
after photobleaching were considered to contain immobile protein aggregates [18]. We demon-
strated that h-proIAPP expression in C. elegans formed insoluble aggregates that do not diffuse
Hsp72 Prevents IAPP Aggregation and Toxicity
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Fig 3. Construction and identification of human andmouse proIAPPC. elegans vectors. A. Schematic representation of human-proIAPP and mouse-
proIAPP tissue-specific vector constructs. cDNA of human and mouse proIAPP with human and mouse signal peptide, respectively, were cloned into the
BamH1 restriction site of the pSX95.77YFP C.elegans vector to generate human and mouse pSX95.77YFP-proIAPP transgenes. Resulting constructs were
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PLOS ONE | DOI:10.1371/journal.pone.0149409 March 9, 2016 9 / 21
digested with Sal1, blunt-ended and ligated into Gateway Cassette C.1 upstream of human and mouse coding sequences to create vectors pNG1 and pNG2.
Destination vectors pNG1 and pNG2 were LR recombined with pLR22, pLR25 and pLR35 entry clones to generate human proIAPP plasmids: pPR3, pPR4
and pPR5 and mouse proIAPP plasmids: pPR8, pPR9 and pPR10.B. h-proIAPP sequence of construct pSX95.77YFP-prohIAPP with human signal peptide.
Preproh-IAPP (1–89) peptide amino acid sequence is shown in black italics. Signal peptide sequence is shown in red.C.m-proIAPP sequence present in
construct pSX95.77YFP-promIAPP with mouse signal peptide. Preprom-IAPP peptide amino acid sequence is shown in black italics. Signal peptide
sequence is shown in red. Restriction sites used in the generation of these plasmids are underlined. No stop codon was included after each proIAPP
sequence.
doi:10.1371/journal.pone.0149409.g003
Fig 4. Expression of h-proIAPP inC. elegans results in protein insolubility and aggregation.
Transgenic h-proIAPP C. elegansmodel was generated by gonad microinjection of 20 ng/μl of plasmids
pPR3, pPR4 and pPR5. Transgenic m-proIAPP C. elegansmodel was generated by gonad microinjection of
20 ng/μl of plasmids pPR8, pPR9 and pPR10.A. h-proIAPP and m-proIAPP tagged with YFP were
expressed in body wall muscles, vulva muscles and anal depressor muscles under lev-11 promoter; in
pharynx under tnt-4 promoter, and in neurons under aex-3 promoter. Neuronal expression of proIAPP
secreted into the body cavity was observed in the coelomocytes of the h-proIAPPmodel and distributed in the
intestinal region in both h-proIAPP and m-proIAPPC. elegansmodels. Images were created using maximum
intensity projections on all the planes of the acquired stacks except coelomocytes where images were taken
in a single plane for better visualization. Arrows indicate areas of fluorescence. DIC images were taken to
visualize structures. Results are a representative experiment from at least three independently performed
experiments with similar results. Scale bars represent 50 μm. B. Data represent the mean fluorescence
intensity (MFI) ± SDmeasured using a sum intensity projection on all the planes of the acquired stacks of m-
proIAPP (open bars) and h-proIAPP (filled bars) tagged with YFP expressed in body wall muscles, vulva
muscles, anal depressor muscles and pharynx. *p<0.05; **p<0.01 versus m-proIAPP. C. Transgenic h-
proIAPPC. elegans tagged with YFP were subjected to FRAP analysis (square). Data are from vulva
muscles (row 1), anal depressor (row 2), pharynx (row 3) and coelomocytes (row 4) before FRAP (left
panels), 10 seconds after FRAP (middle panels) 250 seconds after FRAP (right panels). Images were
obtained using an inverted confocal microscope. Results are representative experiment from at least three
independently performed experiments with similar results. Scale bars represent 50 μm.
doi:10.1371/journal.pone.0149409.g004
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to restore fluorescence of the photobleached region. This phenomenon was observed in vulva
muscles, anal depressor muscles, pharynx and coelomocytes of animals expressing h-proIAPP
(Fig 4C).
Human-proIAPP-induced aggregates mediates developmental
retardation in the C. elegans
We next examined the effect of h-proIAPP aggregates on C. elegans behavioral phenotypes.
We initially measured life span of all three transgenic model systems (pBX1, m-proIAPP and
h-proIAPP) and did not find any statistically differences (data not shown). We next measured
the rate of development by synchronizing worms with hypochlorite treatment as described in
detail in the Material and Methods section. Seventy hours after treatment, larvae stage was
determined and compared with the pBX1 controls. We demonstrated significant developmen-
tal retardation in the transgenic h-proIAPP C. elegans, as compared to the m-proIAPP and
pBX1 controls (Fig 5).
Hsp72 expression improves the solubility of h-proIAPP in the C. elegans
model
To demonstrate the effect of Hsp72 in protein aggregation, we constitutively co-expressed h-
proIAPP tagged with YFP together with h-Hsp72 in C. elegans body-wall muscles (lev-11 pro-
moter). Transgenic h-Hsp72 and h-proIAPP C. elegans animals were generated by gonad co-
injection of 20ng/μl of h-proIAPP tagged with YFP expressed in body-wall muscles (plasmid
pPR3) and 30ng/μl of Hsp72 expressed in the same tissue (plasmid pPR21). C. elegans injected
with 20ng/μl of plasmid pPR3 was used as a control for protein aggregation. To serve as a solu-
ble control, a plasmid that carries only YFP expressed in body-wall muscles (plasmid pPR18)
was created. YFP plasmid (pPR18, 20ng/μl) together with Hsp72 plasmid (pPR21, 30ng/μl)
expressed in the same tissue were microinjected to generate a transgenic C. elegansmodel sys-
tem that expresses both YFP and Hsp72 in body-wall muscles.
To evaluate differences in solubility, we used FRAP analysis. The rate of recovery after
photobleaching was used as a measure of protein solubility and allowed us to discriminate pro-
tein aggregates in which interacting proteins are immobile and insoluble. FRAP experiments
on live animals that express soluble YFP + Hsp72 control, demonstrated significantly greater
recovery after photobleaching (Fig 6A; top panels), while protein aggregates of transgenic h-
proIAPP C. elegans animals did not recover after photobleaching, indicating the presence of
immobile and insoluble aggregates (Fig 6A; middle panels). FRAP analysis of transgenic h-
proIAPP + Hsp72 C. elegans demonstrated significantly increased solubility (Fig 6A; bottom
panels). Quantification of relative fluorescence intensity over time provides further evidence of
the ability of Hsp72 to improve h-proIAPP solubility (Fig 6B).
ADAPT-232 improves transgenic h-proIAPP C. elegans phenotype
To test the hypothesis that transgenic C. elegans expressing h-proIAPP can be used to evaluate
potential drugs that decrease h-proIAPP aggregation, we used ADAPT-232 as a therapeutic
candidate. ADAPT-232 was used at a concentration of 1mg/ml in NGM ADAPT-supple-
mented agar plates. It was previously demonstrated that the active ingredients of ADAPT-232
induced the expression of the C. elegans stress-inducible hsp-16 [9]. We demonstrated that
treatment of transgenic h-proIAPP C. elegans with ADAPT-232 significantly improved its
growth retardation phenotype as compared to the untreated h-proIAPP animals (Fig 7).
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Fig 5. Expression of h-proIAPP inC. elegans correlates with growth retardation phenotype. Developmental phenotype was studied in transgenic h-
proIAPPC. elegansmodel, transgenic m-proIAPPC. elegansmodel and pBX1 control animals by quantifying the number of animals in the larvae 1 (L1) to
larvae 3 (L3) stages (open bars) versus larvae 4 (L4) and adult stages (filled bars) seventy-two hours after ten to fifteen gravid hermaphrodites were treated
with bleach to release eggs. Data represent the percentage of animals found at larvae 1 to larvae 3 stages and the percentage of animals found at larvae 4
and adult stages ± S.D. p<0.05 versus respective control, n = 3.
doi:10.1371/journal.pone.0149409.g005
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Fig 6. Hsp72 expression improves the solubility of h-proIAPP aggregates. A. Transgenic YFP + Hsp72C. elegansmodel was generated by co-injection
of 20 ng/μl of plasmid pPR18 (that expresses YFP in muscles) together with 30 ng/μl of Hsp72 expressed in the same tissue (plasmid pPR21) to serve as a
soluble control (top panels).C. elegans injected with 20 ng/μl of h-proIAPP tagged with YFP expressed in muscles (plasmid pPR3) was used as a control for
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protein aggregation (middle panels). Transgenic h-proIAPP::YFP + Hsp72C. elegans animals were generated by gonad co-injection of 20 ng/μl of plasmid
pPR3 and 30 ng/μl of plasmid pPR21 (bottom panels). Transgenic animals were subjected to FRAP analysis (square). Data was collected before
photobleaching (left panels), 10 seconds after photobleaching (middle panels) and 250 seconds after photobleaching (right panels). Images were obtained
using an inverted confocal microscope. Results are representative of one experiment from at least three independently performed experiments with similar
results. Scale bars represent 50 μm. B. Data represents the quantification of relative fluorescence intensity, RFI ± SEM during recovery after photobleaching
of transgenic h-proIAPP::YFP C. elegansmodel (filled circles), transgenic h-proIAPP::YFP + Hsp72 C. elegans animals (open circles), and transgenic YFP
+ Hsp72 C. elegansmodel (filled triangles). Data are the mean of at least three independently performed experiments. *p<0.05 versus h-proIAPP::YFP, Error
Bar = SEM.
doi:10.1371/journal.pone.0149409.g006
Fig 7. ADAPT-232 improves transgenic h-proIAPPC. elegans phenotype. Developmental phenotype was studied in the transgenic h-proIAPPC.
elegansmodel by the evaluation of larvae or adult stages seventy-two hours after ten to fifteen gravid hermaphrodites were treated with bleach and larvae
was placed in an agar plate containing 1mg/ml of ADAPT-232. Data represent the percentage of animals found at larvae 1 (L1) to larvae 3 (L3) stages (open
bars) and the percentage of animals found at larvae 4 (L4) and adult stages (filled bars) ± S.D. and are the mean of three independently performed
experiments. p<0.05 versus respective control.
doi:10.1371/journal.pone.0149409.g007
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Discussion
This study was undertaken to determine the contribution of Hsp72 (HSPA1A) in preventing
the toxic aggregation of h-proIAPP and h-IAPP which are the main components of intracellu-
lar amyloid [4]. We demonstrated that overexpression of Hsp72 (HSPA1A) by thermal stress
or by transfection procedures protects pancreatic β-cells against exogenous and endogenous h-
IAPP toxicity. Consistent with these results, we demonstrated that Hsp72 (HSPA1A) improves
the solubility of h-proIAPP aggregates in a C. elegans in vivomodel. Sodium azide was used at
5mM for approximately 5 to 6 minutes to immobilize the worms during imaging. Although,
sodium azide is a metabolic inhibitor and a known inducer multiple heat shock proteins. The
concentration and time of exposure to the worms we used in this study is not sufficient to
induce heat shock proteins. This is in agreement with studies by Massie and coworkers who
report heat shock protein-induction at 10 mM of sodium azide after 90 minutes exposure [21].
Hsp72 protects pancreatic β-cells against in vitro h-IAPP toxicity
We demonstrated that heat shock treatment at 43°C and the overexpression of Hsp72 protect
pancreatic β-cells against h-IAPP-induced toxicity (Figs 1 and 2). We propose that an important
mechanism of protection involves the molecular chaperoning activity of Hsp72 that promotes
folding and refolding of proteins prone to aggregate. Previous studies have demonstrated that in
vitroHsp72 suppresses h-IAPP misfolding, as judged by thioflavin-T fluorescence analysis [22].
We wanted to demonstrate a protein-protein interaction between Hsp72 and h-IAPP after both
proteins were co-expressed in β-cells by transient transfection. However, we were not able to
demonstrate such interactions either by co-immunoprecipation experiments or cross-linking
procedures (data not shown). We speculated that these are transient interactions in which Hsp72
temporarily stabilizes h-IAPP and prevents its aggregation. Moreover, co-immunoprecipitation
only detects proteins that remain in physiological complexes after solubilization from the cell,
therefore if the complexes form large aggregates, these may not be detected. This proposed mech-
anism positions Hsp72 as a very promising candidate for the treatment of conformational dis-
eases in which misfolded protein aggregates are responsible of cell toxicity.
Toxic aggregates observed in the h-proIAPP C. elegansmodel correlate
with growth retardation phenotype
We generated a novel transgenic C. elegansmodel that expresses h-proIAPP tagged with YFP
for easier visualization. In these transgenic animals, a muscle promoter, pharyngeal promoter
and pan-neuronal promoter were used to express a potentially secretable form of proIAPP that
contained a signal-peptide sequence. This model was designed to mimic the initial fibril forma-
tion as observed in pancreatic β-cell secretory granules and to elucidate whether abnormally
increased amounts of unprocessed and highly amyloidogenic proIAPP participate in the pro-
cess of tissue (i.e., islet) destruction. It has been demonstrated that proIAPP is a constitutive
part of the amyloid found in secretory granules by using antibodies against proIAPP NH2- and
COOH-terminal sites [4]. Moreover, there is evidence of toxicity by IAPP oligomers in the ER
of human pancreatic β-cells [23]. Given the fact that in the ER proIAPP is the predominantly
existing form, it is most probable that the formation of oligomers, in this location, results from
the presence of highly concentrated unprocessed proIAPP. Since all individuals secret amyloi-
dogenic IAPP but only some of them develop type 2 diabetes, an imbalance in the proIAPP:
IAPP ratio within the secretory granules may be a very important feature in the pathogenesis
of the disease [24], and prolonged hyperglycemia may lead to a higher proportion of unpro-
cessed proIAPP [25].
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Biologically active peptides are synthesized as larger inactive pre-proproteins that contain
an amino terminal signal peptide that is cleaved off upon entrance into the secretory pathway.
This is the case of proIAPP in which prohormone convertase 2 (PC2) and prohormone conver-
tase 1/3 (PC1/3) convert proIAPP into IAPP. Then, carboxypeptidase E removes the COOH-
terminal dibasic amino acids. In C. elegans, four proprotein convertase genes were found. One
of these is the kpc-2/egl-3 gene, which encodes a PC2-like convertase that is the major active
proprotein convertase in neurons [26]. In addition, carboxypeptidase E. egl-21 gene encodes a
neural-specific carboxypeptidase E [27]. It is probable that h-proIAPP in our C. elegansmodel
is being cleaved by EGL3/KPC2 and egl-21 carboxypeptidase E, at least when expressed in neu-
rons. Further investigation of proIAPP cleavage into a mature IAPP form, needs to be
performed.
We demonstrated that h-proIAPP forms insoluble aggregates (Fig 4C) and that these aggre-
gates correlate with a growth retardation phenotype (Fig 5). Although the physiological basis
for this phenotype is not clear, it is very likely that this phenotype results from body muscle cell
and pharynx muscle cell toxicity, since h-proIAPP expressed in neurons is completely secreted
and accumulated in the coelomocytes. Conversely, Drosophila Melanogaster expressing h-
proIAPP and h-IAPP have been shown to form aggregates in CNS and fat body region and
flies expressing h-proIAPP in neurons showed a reduction in lifespan [28]. Toxicity can also be
explained by the ability of amyloid fibrils to interact with other proteins resulting in sequestra-
tion and loss of function of the sequestered proteins [29]. Amyloid fibrils are prone to sequester
components of the chaperone system [30]. Molecular chaperones, in their attempt to prevent
misfolding or help with refolding activities, may get trapped within the fibrils and are pre-
vented from exerting their chaperoning activities. This will result in the collapse of the chaper-
one system and propagation of folding problems along the cell. A manifestation of this toxicity
may be evidenced by a development retardation phenotype exhibited by the h-proIAPP C. ele-
gansmodel in which highly fluorescent protein aggregates were observed (Fig 4A; right panels
and Fig 4B). Proteostasis mechanisms may not be sufficient in preventing the misfolding of the
highly amyloidogenic h-proIAPP form. Conversely, protective mechanisms in the m-proIAPP
C. elegansmodel, which expresses a protein less prone to aggregate, seem to prevent massive
aggregation and a rapid clearance response was evidenced by less aggregate accumulation and
reduced fluorescence intensity in their tissues (Fig 4A; left panels and Fig 4B). This is also sup-
ported by a milder developmental retardation phenotype.
Secreted h-proIAPP is taken up by C. elegansmacrophages
(coelomocytes)
We were able to demonstrate that h-proIAPP expressed in neurons was secreted into the body
cavity and accumulated in the coelomocytes. Adult C. elegans hermaphrodites have six fixed
coelomocytes that have a phagocytic function similar to the macrophages of vertebrates (www.
wormatlas.org). It seems that these coelomocytes scavenge h-proIAPP aggregates secreted
from neurons in an attempt to destroy these foreign aggregates. The fact that coelomocytes in
the h-proIAPP model remain highly fluorescent (Fig 4A and S3 Fig) supports the inability of
these cells to destroy the aggregates. These results are in agreement with studies of cytoplasmic
inclusions found in h-IAPP transgenic rat islets due to a decreased lysosomal degradation of h-
IAPP toxic oligomers [31]. However, we demonstrated that not all proIAPP-expressed protein
was detected extracellularly. We speculate that proIAPP deposition in pharynx and to some
extent in body wall muscles may preclude extracellular secretion. Further determination of the
intra- or extracellular localization of proIAPP deposits may help elucidate the fate of this pep-
tide in muscle and pharynx cells of proIAPP transgenic animals.
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Hsp72 enhances h-proIAPP solubility and improves growth retardation
phenotype in h-proIAPP C. elegansmodel
We demonstrated that co-expression of h-proIAPP and Hsp72 in a C. elegansmodel results in
improved h-proIAPP solubility (Fig 6A and 6B). Similarly, the overexpression of members of
the HSP70 family inhibited the formation of toxic oligomers and prevented the formation of
amyloid aggregates in polyglutamine-repeat disorders, in which Hsp70 cooperates with the
chaperonin TRiC [32]. Moreover, Hsp70 prevented dopaminergic neuronal loss associated
with alpha-synuclein in a Drosophilamodel [33]. A genome-wide RNAi screen in an alpha-
synuclein C. elegansmodel identified two chaperones, members of the HSP70 and HSP90 fami-
lies that when knocked-down, promoted aggregation [34]. In a biochemical approach to iden-
tify chaperones that were associated with amyloid β in a C. elegansmodel; two members of
HSP70 family were found as well as three small heat shock proteins [35]. On the basis of these
findings, the pharmacological upregulation of the chaperone system gives us a new alternative
to control aberrant protein misfolding and aggregation in various conformational diseases. As
a proof-of-principle, some small molecules that are regulators of the heat shock response such
as radicicol and geldamycin were successfully used to inhibit the formation of Huntingtin
aggregates in in vitro studies [36]. Likewise, a group of plant extracts called adaptogens were
identified for their property to reinforce a non-specific adaptive capacity to resist stress condi-
tions and to facilitate a more rapid return to normality [9]. It was demonstrated that adapto-
gens induced the translocation of the transcription factor DAF-16 in C. elegans (FOXO in
humans) into the nucleus [9]. Several genes regulated by DAF-16 are involved in stress resis-
tance, longevity and autophagy [37], a process required for the removal of protein aggregates.
Moreover, adaptogens increased the synthesis of the C. elegans stress-inducible Hsp-16 (Wie-
gant et al. 2009). Therefore, adaptogens may target two important mechanisms of cell protec-
tion against toxic aggregates, a) by increasing the levels of molecular chaperones, which
prevent the formation of aggregates, and b) by promoting the autophagic degradation of toxic
aggregates.
Adaptogens were successfully used in animal models of aging related disorders and confor-
mational diseases. Panossian et al., demonstrated that ADAPT-232 increased Hsp72 serum lev-
els in mice and protected them against stress (Panossian, et al. 2009). Moreover,
Eleutherococcus senticocus and Rhodiola rosea prolonged the lifespan of N2 wild-type C. ele-
gans strain in a dose-dependent manner and increased stress resistance against acute and
chronic heat stress and against chronic oxidative stress conditions (Wiegant et al. 2009). The
same effect was evidenced in Drosophila melanogaster, where Rhodiola rosea showed to
increase its lifespan [38]. Bai et al., demonstrated that Eleutherococcus senticocus extracts pro-
motes the regeneration of neuritic atrophy and synaptic loss caused by amyloid β in rat cul-
tured cortical neurons [39]. In this study, we demonstrated that plant adaptogens (ADAPT-
232) were able to improve h-proIAPP C. elegans phenotype (Fig 7). Taken together, these
results suggest that adaptogens may be used as a potential drug to treat type 2 diabetes. Other
heat shock response modulators, previously used for other protein conformational diseases,
including curcumin, geldanamycin and radicicol [40, 41] should be studied for their efficacy in
this model.
In conclusion, our in vitro studies show that Hsp72 (HSPA1A) ameliorates exogenous and
endogenous h-IAPP toxicity. Thus, interventions designed to increase the levels of Hsp72 in
pancreatic β-cells may constitute potential treatments for type 2 diabetes. The C. elegansmodel
described in this study does not replicate all aspects of type 2 diabetes, but it captures a very
important mechanism of pancreatic β-cell toxicity mediated by h-proIAPP aggregation.
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Additionally, this model allows researchers a fast and effective technique to investigate factors
and potential drugs than can modulate h-proIAPP aggregation.
Supporting Information
S1 File. Supporting Information.
(DOCX)
S1 Table. Primers used in current study.
(DOCX)
S1 Fig. DS-Red::h-IAPP transfection in Beta-TC6 cells. Cells that exhibited strongest red
fluorescence were round and detached A. Fluorescence image (left), phase contrast image
(middle), fluorescence and phase contrast overlaid image (right), using 40 X magnifications, 24
hours after transfection. B. Fluorescence image (left), phase contrast image (middle), fluores-
cence and phase contrast overlaid image (right), using 40 X magnifications, 48 hours after
transfection.
(TIF)
S2 Fig. Identification of positive proIAPP clones by colony PCR. Top panel; lane 1, 1-kb
DNA ladder; lane 2–11, DNA extracted from various h-proIAPP colonies; lane 12, h-proIAPP
vector (Origene) as a positive control. Bottom panel; lane 1–10, DNA extracted from different
m-proIAPP colonies; lane 11, pCMV6 (Origene) as a negative control; lane 12, 1-kb DNA lad-
der.
(TIF)
S3 Fig. Coelomocytes in the h-proIAPP transgenic C. elegansmodel. A. h-proIAPP adult C.
elegans ventral coelomocytes and B. Dorsal coelomocytes images obtained with a fluorescent
microscope at 40X magnification. Coelomocytes are suggested to be phagocytic and similar in
function to the macrophages of vertebrates. They have a relatively fixed position in the body
cavity. C. h-proIAPP coelomocytes fluorescence images andD. Phase contrast images using
100X magnification.
(TIF)
S4 Fig. Gene transcript level in h-proIAPP and m-proIAPP C. elegansmodels. RT-PCR was
performed on h-proIAPP and m-proIAPP worms and PCR samples were taken at 25, 27 and
29 cycles of amplification and semi-quantified by visualization following electrophoresis in
1.5% agarose gels. Lane 1, 1-kb DNA ladder; lane 2, PCR product taken at 25 cycles of amplifi-
cation of m-proIAPP gene; lane 3, PCR product taken at 25 cycles of amplification of h-
proIAPP gene; lane 4, PCR product taken at 27 cycles of amplification of m-proIAPP gene;
lane 5, PCR product taken at 27 cycles of amplification of h-proIAPP gene; lane 6, empty; lane
7, PCR product taken at 29 cycles of amplification of m-proIAPP gene; lane 8, PCR product
taken at 29 cycles of amplification of h-proIAPP gene.
(TIF)
S5 Fig. Acute inducible expression of h-proIAPP in a C. elegansmodel driven by hsp-16-2
promoter, correlates with high number of aggregates.Mouse and human pro-IAPP tagged
with YFP expressed under the inducible hsp-16-2 promoter were observed in A, pharynx; B,
body wall muscles; C, intestine, after animals were exposed to heat stress at 33°C for 90 min-
utes. Images were obtained using a fluorescent microscope at 40X magnification. Arrows indi-
cate areas of aggregation.
(TIFF)
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